1\. Histologically or cytologically confirmed advanced solid tumors, with specific tumor type and prior treatment requirements per each cohort;
2\. Measurable disease per RECIST v1.1 (except Cohorts 3B-1, 3B-2, and 5B);
3.Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
4.Adequate organ function;
5.Recover from all reversible AEs from previous anti-tumor treatment (i.e., Grade ≤ 1, according to NCI-CTCAE v6.0), excluding alopecia (any grade) and Grade ≤ 2 neuropathy peripheral;.
You may not be if
1.Prior treatment with CDH6-targeted agents or topoisomerase I inhibitors (including ADCs);
2.Prior treatment with immune checkpoint inhibitors (for Cohorts 2 and 6 only);
3.Prior Grade 4 or persistent ≥ 4-week Grade 3 immune-related AEs from immune checkpoint inhibitors;
4.Prior systemic anti-tumor therapy (for Cohorts 1B-2 and 2B-2 only);
5.Recent anti-tumor therapy within specified washout periods (small molecules: 2 weeks; biologics/chemotherapy: 4 weeks; mitomycin/nitrosoureas: 6 weeks);
6.Active or symptomatic CNS metastases or leptomeningeal carcinomatosis;
7\. Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection;
8.History of significant cardiac disease, or poorly controlled diabetes mellitus;
9.History of recurrent autoimmune diseases;
10\. History of a second primary malignancy;
11.Be allergic to any component of QLS5133 or its excipients.